活性维生素D_3对糖尿病大鼠肾组织SHIP2表达及多态性的影响被引量：1

Effect of active Vitamin D_3 on the expression of SHIP2 gene single nucleotide polymorphism in glomeruli of rats with diabetic nephropathy

下载PDF

导出

摘要目的:研究SHIP2基因多态性与糖尿病肾病(DN)的关系,观察应用活性维生素D[1,25-(OH)2D3]干预对SHIP2表达的影响。方法:选择健康雄性Wistar大鼠30只经腹腔注射链佐脲菌素(STZ)制备糖尿病模型,在糖尿病模型制备后给予1,25-(OH)2D30.03ng·g-1·d-1皮下泵入,连用8周。于模型成功后检测大鼠血糖(Glu)、24h尿蛋白(24hUP)、血肌酐(Scr)、尿足细胞(UPC)。采用RT-PCR检测肾小球SHIP2基因多态性的表达。结果:Vit D3治疗后,SHIP2基因SNP5AA/AC Glu、24hUP较CC型明显下降,差异具有统计学意义(P<0.05)。结论:SHIP2基因SNP5为AA/AC型者对Vit D3的治疗反应优于GG型者。SHIP2基因SNP5多态性可能影响Vit D3对T2DM患者的治疗效果。 Objective. To explore the relationship of nucleotide polymorphismobserve, and to ob- serve the effect of active vitamin D3 on the expression of SHIP2 gene single nucleotide polymorphism in glomeruli of rats with diabetic nephropathy（DN）. Methods： After 30 healhty Wistar rats diabetes models were successfully established by peritoneal injection of streptozotocin（STZ）, they were embedded with the osmotic minipump for giving 0. 03 ng ·g^-1 . d^-1 active vitamin D3 for 8 weeks. Blood glucose （Glu）, the ratio of 24-hoururinary protein（24 hUP）, serum creatinine（Scr） and urinary podoctye（UPC） were meas- ured. The expression and distribution of SHIP2 gene single nucleotide polymorphism in glomeruli was de- tected by indirect PCR-RFLP. Results. After Vit D3 treatmen, the levels of Glu （FPG） and 24hUP in the AG/AA genotype decreased significantly comparing with the AG/AA genotype （P〈0. 05）. Conclusion： T2DM rats with AG/AA genotype in the GG gene have a better therapeutic response to Vit D3 than pa- tients with AG/AA genotype.

作者孙文早王亮黄晶邹毅

机构地区仙桃市第一人民医院内分泌科

出处《海南医学院学报》 CAS 2014年第7期873-876,共4页 Journal of Hainan Medical University

基金湖北省自然科学基金(hb2018212)~~

关键词活性维生素D3 SHIP2 糖尿病肾病 1, 25-（OH）2D3 SHIP2 Diabetic nephropathy

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献14

1Tan B, Zhang YF, Chen XY, et al. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects[J]. Eur J Clin Pharmacol, 2010, 66(2) : 145-151.
2Zhang KH,Huang Q,Dai XP,et al. Effects of the peroxisome proliferator activated receptor-γ coactivator-1 a (PGC-1a)Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus [J]. J Clin Pharmacol, 2010, 50 (9) : 1022-1030.
3Swen J J, Guchelaar HJ, Baak-Pablo RF, et al. Genetic risk factors, for type 2 diabetes mellitus and response to sulfonylurea treatment [J]. Pharmacogenet Genomics, 2011,21(8) :461-468.
4Tarasova L,Kalnina I,Geldnere K,et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients [J]. Pharmacogenet Genomics, 2012, 22 (9) :659-666.
5Meerza D, Naseem I, Ahmed J. Can Vitamin D be a potential treatment for Type 2 diabetes mellitus[J]. Diabe tes and Metabolic Syndrome: Clinical Research and Reviews, 2010, 4(4): 245-248.
6von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial [J].Br J Nutr, 2010, 103(4) : 549-555.
7尹晓,阎玲,陆勇.维生素D干预治疗对肥胖及相关代谢异常的影响[J].山东大学学报（医学版）,2011,49(3):1-4. 被引量：7
8Kojima G, Bell C, Abbott RD, et al. Low Dietary Vita min D Predicts 34-Year Incident Stroke The Honolulu Heart Program[J]. Stroke, 2012,43(8) : 2163-2167.
9谷丽娟,刘建萍,霍亚南,刘精东.血清1,25-二羟维生素D_3水平与糖尿病肾病的关系研究[J].中国全科医学,2011,14(34):3936-3939. 被引量：26
10Levin A, Le Barbier M, Er L, et al. Incident isolated 1, 25-(OH) 2D3 deficiency is more common than 25(OH) D deficiency in CKD[J]. J Nephrol, 2012,25 (2) : 204- 210.

二级参考文献50

1Sasaoka T, Wada T, Tsuneki H. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity. Pharmacol Ther, 2006, 112 : 799 - 809.
2Asano T, Fujishiro M, Kushiyama A,et al. Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions. Biol Pharm Bull, 2007, 30 : 1610- 1616.
3Wada T, Sasaoka T, Funaki M, et al. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity. Mol Cell Biol, 2001, 21 : 1633- 1646.
4Sasaoka T, Hori H, Wada T, et al. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes. Diabetologia, 2001,44 : 1258 - 1267.
5Fukui K, Wada T, Kagawa S, et al. Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5'-phosphatase 2 ) on insulin signaling and glucose metabolism in mice. Diabetes, 2005, 54 : 1958- 1967.
6Kagawa S, Soeda Y, Ishihara H, et al. Impact of Transgenic Overexpression of SH2-Containing Inositol 5'-Phosphatase 2 on Glucose Metabolism and Insulin Signaling in Mice. Endocrinol, 2008, 149 : 642- 650.
7Kaisaki PJ, Delepine M, Woon PY, et al. Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome. Diabetes, 2004, 53 : 1900 - 1904.
8Grempler R, Zibrova D, Schoelch C, et al. Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice. Diabetes, 2007, 56 : 2235 -2241.
9Buettner R, Ottinger I, Gerhardt-Salbert C, et al. Antisense oligonucleotides against the lipid phosphatase SHIP2 improve muscle insulin sensitivity in a dietary rat model of the metabolic syndrome. Am J Physiol Endocrinol Metab, 2007, 292 : E1871 -1878.
10Vandeput F, Backers K, Villeret V , et al. The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase activity. Cell Signal, 2006, 18 : 2193 -2199.